Interim PET in DLBCL: the Swiss experience

Luca Ceriani
Oncology Institute of Southern Switzerland
Bellinzona
Interim PET in DLBCL: the Swiss experience

Two ongoing studies:

➢ **SAKK** - Swiss Group for Clinical Cancer Research

**Trial 38/07**

Current status: open  
Enrollment: complete  
Recruitment from Swiss centers

Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)

➢ **IELSG** - International Extranodal Lymphoma Study Group

**Trial 26**
A clinico-pathologic study of Primary Mediastinal B-cell lymphoma

Current Status: open  
Enrollement: complete  
Recruitment from International centers

Estimate closure Date 31/05/2010
Interim PET in DLBCL: the Swiss experience

**SAKK** - Swiss Group for Clinical Cancer Research

**Trial 38/07**


**OBJECTIVE:**

To evaluate if an early positive positron emission tomography (PET) scan after 2 courses of R-CHOP 14 can be used to identify a group of patients having a poor prognosis.
SAKK- 38-07

**SELECTION OF PATIENTS (MOST IMPORTANT CRITERIA)**
- Histologically proven diagnosis of CD20+ DLBCL
- PET+
- Measurable lesion with CT
- Age: 18-80 years
- ECOG/WHO Performance status 0–2
- Sufficient medical condition
- No prior chemotherapy, radiotherapy or immunotherapy for lymphoma
- No secondary DLBCL (Transformation)
- No concomitant or any hematological malignancies in the past
- No evidence of symptomatic CNS disease

**Baseline PET-CT**

2 x R-CHOP-14

**Interim PET-CT after 2 cycles**

- SD PR CR
- PET+
- PET-

2 x R-CHOP-14

**Interim PET-CT after 4 cycles**

2 x R-CHOP-14, followed by 2 x R

**Final PET-CT**

(3-4 weeks after ChT)

Follow-up

**Treatment at the discretion of the investigator**
SAKK- 38-07 Preliminary Results

interim PET positivity after the 2\textsuperscript{nd} R-CHOP\textsubscript{14} cycle (n=76/ 156)

- Definition: max Uptake > max bloodpool + 15%

\begin{center}
\begin{tikzpicture}
    \begin{axis}[
        ybar,        ymajorgrids,        xlabel={},        ylabel={\%},        symbolic x coords={pos, neg},        xtick=data,        nodes near coords,        nodes near coords align={vertical},        enlarge x limits=0.2,        every node near coord/.append style={/pgf/number format/1000 sep={}},        
    
    \addplot coordinates {(pos, 48.7) (neg, 51.3)};
\end{axis}
\end{tikzpicture}
\end{center}

By the courtesy of Dr. Ch. Mamot - Aarau

Nuclear Medicine Dpt. - PET/CT centre
Interim PET in DLBCL: the Swiss experience

IELSG - International Extranodal Lymphoma Study Group

Trial 26
A clinico-pathologic study of Primary Mediastinal B-cell lymphoma

MAIN OBJECTIVE:

To obtain data on PET-CT response rate at the end of treatment in the R-chemo era, prior to design a subsequent randomized trial of consolidation RTh

Interim PET (not reimbursed by health insurances in several countries at the time the study was designed) was not mandatory
IELSG- 26

Pts with primary mediastinal DLBCL

Registration for trial - central review of pathology

Baseline PET
(within 14 days before ChT)

Interim PET (*)
(after half of planned ChT)

Final PET
(3-4 weeks after ChT)

Full course of chemotherapy:
R-CHOP 21
R-CHOP 14
R-MACOP - B
R-VACOP - B
R-ACVBP

(*) suggested, not mandatory

Restaging

Consolidation radiotherapy according to local protocol

Follow-up

post RTh - PET
(at least 2 months after RTh)

Nuclear Medicine Dpt. - PET/CT centre
IELSG 26

Preliminary data - PET local interpretation

- Criteria for PET (-): Visual analysis negative or SUV max target lesion < SUV max blood pool aorta

Baseline: 45 PET +

Interim:
- 24 PET +
- 21 PET -

Final:
- 17 PET +
- 28 PET -

post RTh:
- 7 PET +
- 38 PET -

% Positive (95% C.I.):
- Interim: 53% (38-68)
- Final: 38% (24-53)
- post RTh: 16% (6-29)
IELSG 26
Preliminary data - PET local interpretation

DLBCL

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Interim</th>
<th>Final</th>
<th>post-Rt</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUV max</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>